Literature DB >> 11035907

Glucocorticoid-induced osteoporosis.

I R Reid1.   

Abstract

Glucocorticoid drugs interact with bone metabolism at many levels, but their principal action is to reduce osteoblast number and bone matrix synthesis. Virtually all patients receiving glucocorticoids in doses above 5 mg per day lose bone, the amount lost being dependent on the cumulative steroid dose. The risk of fracture is also related to the individual's initial bone density, which in turn reflects race, sex, age, menopausal status, body weight, smoking and the nature of any underlying illness. Bone density measurement and personal fracture history are the best predictors of future fracture risk. Steroid-induced bone loss is reversible, so measures to minimize the systemic steroid dose or to withdraw these drugs altogether should be pursued no matter how long an individual has been using them. Increasing the calcium intake to 1.5 g per day, encouraging them to stop smoking and take more exercise, and treating any vitamin D deficiency are sensible measures in all patients. In those at high risk, bisphosphonates are the best documented interventions, although sex hormone replacement is also effective and can be used alone or in addition to bisphosphonates. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11035907     DOI: 10.1053/beem.2000.0074

Source DB:  PubMed          Journal:  Baillieres Best Pract Res Clin Endocrinol Metab


  17 in total

1.  Shear stress induces osteogenic differentiation of human mesenchymal stem cells.

Authors:  Gregory Yourek; Susan M McCormick; Jeremy J Mao; Gwendolen C Reilly
Journal:  Regen Med       Date:  2010-09       Impact factor: 3.806

2.  Glucocorticoid use and its association with skeletal health among U.S. adults with diabetes.

Authors:  Sarah Stark Casagrande; Catherine C Cowie; Saul Malozowski
Journal:  J Diabetes Complications       Date:  2016-06-27       Impact factor: 2.852

3.  Bone mineral density before and after surgical cure of Cushing's syndrome due to adrenocortical adenoma: prospective study.

Authors:  Akiko Kawamata; Masatoshi Iihara; Takahiro Okamoto; Takao Obara
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

Review 4.  Corticosteroid-induced adverse events in adults: frequency, screening and prevention.

Authors:  Laurence Fardet; Abdulrhaman Kassar; Jean Cabane; Antoine Flahault
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

5.  Discovery of GW870086: a potent anti-inflammatory steroid with a unique pharmacological profile.

Authors:  I J Uings; D Needham; J Matthews; M Haase; R Austin; D Angell; K Leavens; J Holt; K Biggadike; S N Farrow
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

6.  A glucocorticoid-induced leucine-zipper protein, GILZ, inhibits adipogenesis of mesenchymal cells.

Authors:  Xingming Shi; Weibin Shi; Qingnan Li; Buer Song; Mei Wan; Shuting Bai; Xu Cao
Journal:  EMBO Rep       Date:  2003-03-14       Impact factor: 8.807

7.  Bone mineral density at diagnosis and following successful treatment of pediatric Cushing's disease.

Authors:  S Scommegna; J P Greening; H L Storr; K M Davies; N J Shaw; J P Monson; A B Grossman; M O Savage
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

8.  [Prescription of glucocorticoids by rheumatologists in patients with rheumatoid arthritis in Germany].

Authors:  K Thiele; F Buttgereit; D Huscher; A Zink
Journal:  Z Rheumatol       Date:  2005-04       Impact factor: 1.372

Review 9.  Skeletal sequelae of cancer and cancer treatment.

Authors:  Charles J Stava; Camilo Jimenez; Mimi I Hu; Rena Vassilopoulou-Sellin
Journal:  J Cancer Surviv       Date:  2009-05-02       Impact factor: 4.442

Review 10.  Long-term therapy in COPD: any evidence of adverse effect on bone?

Authors:  Arnulf Langhammer; Siri Forsmo; Unni Syversen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.